AGA临床实践更新:炎症性肠病患者非结直肠癌筛查与疫苗接种专家综述
美国胃肠病学会临床实践更新专家组发布专家综述,针对炎症性肠病患者的非结直肠癌筛查和疫苗接种提出13条最佳实践建议,涵盖年龄适宜癌症筛查、皮肤癌预防、肛门检查、疫苗接种(含新冠、流感、肺炎球菌、带状疱疹等)及骨密度和心理健康筛查,强调医患共同决策并与初级保健医生协作。
要点
- 所有成人IBD患者应接受年龄适宜的癌症筛查,并每年筛查抑郁和焦虑。
- 使用免疫调节剂、抗TNF生物制剂或小分子的患者应每年进行全身皮肤检查。
- 灭活疫苗安全且不加重IBD活动,应尽早接种并尽量停用或减量皮质类固醇。
核心结论
- 专家组基于现有文献和专家意见提出13条最佳实践建议,强调IBD患者应更新非结直肠癌筛查和疫苗接种。
研究设计与样本
- 美国胃肠病学会临床实践更新委员会委托并批准的专家综述,非系统评价,未对证据质量或推荐强度进行正式评级。
主要发现
- 成人IBD患者应接受年龄适宜的癌症筛查;使用免疫调节剂、抗TNF生物制剂或小分子者应每年全身皮肤检查。
- 每次结肠镜检查应行彻底肛周和肛门检查,特别关注肛周克罗恩病、肛门狭窄、HPV、HIV及肛交接受者。
- IBD患者应遵循CDC成人免疫接种计划,但禁用减毒活疫苗;所有18至26岁成人应接种HPV疫苗系列。
- 灭活疫苗安全且不加重IBD活动;所有成人IBD患者应每年接种灭活流感疫苗,65岁及以上应接种高剂量、重组或佐剂流感疫苗。
- 所有19至64岁成人IBD患者应接种初始肺炎球菌疫苗,65岁及以上再接种第二剂;60岁及以上应接种呼吸道合胞病毒疫苗。
关键数值与推荐
- 最佳实践建议1:所有成人IBD患者应接受年龄适宜的癌症筛查。
- 最佳实践建议2:成人女性IBD患者应遵循年龄适宜的宫颈发育不良筛查;数据不足以确定是否需更频繁筛查;鼓励共同决策和个体风险分层。
- 最佳实践建议3:所有成人IBD患者应避免过度暴露于太阳紫外线辐射;使用免疫调节剂、抗TNF生物制剂或小分子者应每年全身皮肤检查;有硫嘌呤使用史者停药后仍应继续每年检查。
- 最佳实践建议4:每次结肠镜检查应行彻底肛周和肛门检查,特别关注肛周克罗恩病、肛门狭窄、HPV、HIV及肛交接受者。
- 最佳实践建议5:胃肠病学临床医生应与成人IBD患者讨论年龄适宜疫苗,并与初级保健提供者分担接种责任;患者应遵循CDC成人免疫接种计划,但禁用减毒活疫苗;接受免疫调节剂者应被告知避免减毒活疫苗;水痘和麻腮风疫苗系列接种史为免疫推定证据;所有18至26岁成人应接种HPV疫苗系列,27至45岁若有新性伴侣可能应接种。
临床怎么用
- 胃肠病学临床医生应与成人IBD患者讨论年龄适宜疫苗,并与初级保健提供者分担接种责任。
- 使用免疫调节剂、抗TNF生物制剂或小分子的患者应每年进行全身皮肤检查,有硫嘌呤使用史者停药后仍应继续。
- 每次结肠镜检查应行彻底肛周和肛门检查,特别关注肛周克罗恩病、肛门狭窄、HPV、HIV及肛交接受者。
- 所有成人IBD患者应每年筛查抑郁和焦虑,筛查阳性者应转诊至初级保健医生或精神健康专家。
- 骨密度检查应考虑用于存在骨量减少/骨质疏松风险因素的IBD患者,无论年龄;无其他因素时,绝经后女性和65岁以上男性应考虑。
局限性
- 本文为专家综述,非系统评价,未对证据质量或推荐强度进行正式评级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: The aim of this American Gastroenterological Association (AGA) Clinical Practice Update (CPU) is to provide Best Practice Advice statements for gastroenterologists and other healthcare providers who provide care to patients with inflammatory bowel disease (IBD). The focus is on IBD-specific screenings (excluding colorectal cancer screening, which is discussed separately) and vaccinations. We provide guidance to ensure that patients are up to date with the disease-specific cancer screenings and vaccinations, as well as advice for mental health and general well-being. METHODS: This expert review was commissioned and approved by the AGA CPU Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership and underwent internal peer review by the CPU Committee and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. The Best Practice Advice statements were drawn from reviewing existing literature combined with expert opinion to provide practical advice on the screening for noncolorectal cancers and vaccinations in patients with IBD. Because this was not a systematic review, formal rating of the quality of evidence or strength of the presented considerations was not performed. Best Practice Advice Statements BEST PRACTICE ADVICE 1: All adult patients with IBD should receive age-appropriate cancer screening. BEST PRACTICE ADVICE 2: Adult women with IBD should follow age-appropriate screening for cervical dysplasia. Data are insufficient to determine whether patients receiving combined immunosuppression or thiopurines require more frequent screening. Shared decision making and individual risk stratification are encouraged. BEST PRACTICE ADVICE 3: All adult patients with IBD should follow skin cancer primary prevention practices by avoiding excessive exposure to the sun's ultraviolet radiation. Patients on immunomodulators, anti-tumor necrosis factor biologic agents, or small molecules should undergo yearly total body skin exam. Patients with any history of thiopurine use should continue with yearly total body skin exam even after thiopurine cessation. BEST PRACTICE ADVICE 4: At every colonoscopy, a thorough perianal and anal examination should be performed. Special attention should be made to inspection of the anal canal of patients with perianal Crohn's disease, with anal stricture, with human papillomavirus, with human immunodeficiency virus, and who engage in anoreceptive intercourse. BEST PRACTICE ADVICE 5: Gastroenterology clinicians should discuss age-appropriate vaccines with adult patients who have IBD and share responsibility with primary care providers for administering these vaccines. Patients with IBD should follow the adult immunization schedule advised by the Centers for Disease Control and Prevention (CDC) for all vaccines with the exception of live vaccines; Patients receiving immune-modifying agents should be counseled against receiving live vaccines; Immunization history to the 2 live pediatric vaccines, varicella and measles, mumps, and rubella vaccine series, is presumptive evidence of immunity. All adults 18 to 26 years of age should receive human papillomavirus vaccine series, and those between 27 and 45 of age years should be vaccinated if they are likely to have a new sexual partner. BEST PRACTICE ADVICE 6: Inactivated vaccines are safe in patients with IBD, and their administration is not associated with exacerbation of IBD activity. We suggest that patients receive vaccines at the earliest opportunity and preferably be off corticosteroids or at the lowest tolerable corticosteroid dose. BEST PRACTICE ADVICE 7: All adult patients with IBD should be evaluated for latent hepatitis B infection. Patients who have previously completed a full hepatitis B vaccine series but are not seroprotected (hepatitis B surface antibody [anti-HBs] <10 mIU/mL) should receive a single challenge dose of hepatitis B vaccine; Four to 8 weeks after this challenge dose, their anti-HBs levels should be measured to evaluate for an amnestic response. An amnestic response, indicated by an anti-HBs level ≥10 mIU/mL (seroprotection), suggests immunologic memory, and no further doses are needed. If no amnestic response is observed, the patient should complete a second full 2- or 3-dose series of hepatitis B vaccination. BEST PRACTICE ADVICE 8: All adult patients with IBD should receive an annual inactivated influenza vaccine. Patients receiving anti-tumor necrosis factor monotherapy or who have undergone a solid organ transplant recipients can benefit from a high-dose influenza vaccine. Adults 65 years of age and older should receive a high-dose, recombinant, or adjuvanted influenza vaccine. Live attenuated intranasal vaccines should be avoided. BEST PRACTICE ADVICE 9: All adult patients with IBD 19 to 64 years of age should receive an initial pneumococcal vaccine, with an subsequent second pneumococcal vaccine administered at 65 years of age and older. BEST PRACTICE ADVICE 10: All adult patients with IBD who are 60 years of age and older should receive a respiratory syncytial virus vaccine. There is no preference for any of the available respiratory syncytial virus vaccines. BEST PRACTICE ADVICE 11: All adult patients 19 years of age and older receiving immune-modifying therapies, or with plans to initiate immune-modifying therapies, should receive a recombinant herpes zoster vaccine series, regardless of their prior varicella vaccination status. BEST PRACTICE ADVICE 12: Bone densitometry should be considered in patients with IBD, regardless of age, when risk factors for osteopenia and osteoporosis are present. These risk factors include low body mass index (<20 kg/m2), >3 months of cumulative corticosteroid exposure, current smoking, postmenopausal status, or hypogonadism. In the absence of other factors, bone densitometry should be considered for postmenopausal women and men 65 years or older. BEST PRACTICE ADVICE 13: All adult patients with IBD should be screened for depression and anxiety annually. Patients who screen positive for depression or anxiety should be referred to the appropriate specialist, be it their primary care physician or a mental health specialist.
引用
- Caldera F, Kane S, Long M, et al. AGA Clinical Practice Update on Noncolorectal Cancer Screening and Vaccinations in Patients With Inflammatory Bowel Disease: Expert Review. Clin Gastroenterol Hepatol. 2025. PMID: 39800200. doi:10.1016/j.cgh.2024.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。